<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27669" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Prenatal Screening(Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kitchen </surname>
            <given-names>Felisha L.</given-names>
          </name>
          <aff>Coliseum Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jack</surname>
            <given-names>Brian W.</given-names>
          </name>
          <aff>Boston University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Felisha Kitchen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Jack declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27669.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Historically, pregnancy was a very tenuous part of a woman's life because of the high mortality rate associated with gestation. In the early 1900s, maternal mortality was 6 to 9 out of 1000 live births, and 100 per 1000 live-born infants died within the first 12 months of life. In 2000, maternal mortality declined to less than 0.1 out of 1000 live births, and infant mortality declined to 7 out of 1000 live births.&#x000a0; Improvements in nutrition and advances in clinical medicine are key factors in the decline in mortality. Today, prevention of mortality is not the only goal but also the prevention of morbidity. Prenatal screening helps practitioners understand the physical needs of a gestating mother to prevent both morbidity and mortality.&#x000a0;<xref ref-type="bibr" rid="article-27669.r1">[1]</xref><xref ref-type="bibr" rid="article-27669.r2">[2]</xref><xref ref-type="bibr" rid="article-27669.r3">[3]</xref></p>
      </sec>
      <sec id="article-27669.s2" sec-type="Function">
        <title>Function</title>
        <p>
<bold>First Trimester</bold>
</p>
        <p>The first 14 weeks of pregnancy are exciting for parents but an important time for screening by their practitioners. The first obstetrical visit should include a general physical examination and pelvic examination. Baseline vital signs along with the physical examination aid a practitioner in assessing the overall physical wellbeing of the gestating mother. At this time, chronic medical and psychological problems can be addressed by the practitioner as well as a prior obstetrical/gynecologic history. The pelvic examination should include cervical cytology (i.e., Pap smear) if one has not been collected within the past 12 months and the female patient is greater than or equal to 21 years old. Testing for Neisseria gonorrhea and Chlamydia trachomatis should also be performed. The uterus, adnexa, and cervix should be palpated in a bimanual pelvic examination to determine if masses or other abnormalities are present.&#x000a0;</p>
        <p>One of the most important things to determine during the first trimester is a gestational age and estimated due date.&#x000a0; Often, the gestational age is calculated from the last menstrual period if it is known by the patient.&#x000a0; If the last menstrual period is not known or the uterine size does not correlate with the estimated due date by the last menstrual period, an ultrasound for dating takes place.&#x000a0; Ultrasound in the first trimester gives the most accurate gestational age and estimated due date.&#x000a0; The ultrasonographer will assess live fetal status by measuring cardiac activity as well as assess the number of fetuses, amniotic sacs, and placentas. &#x000a0;The ultrasonographer will calculate an estimated gestational age by measuring the crown-rump length of the fetus.&#x000a0; This examination will also detail if uterine or adnexal abnormalities are present.&#x000a0;</p>
        <p>Laboratory tests are often performed during the first prenatal visit.&#x000a0; An assessment of Rh factor and abnormal antibodies, serological tests for syphilis and rubella and either a hemoglobin or hematocrit are required in most institutions.&#x000a0; The American College of Obstetricians and Gynecologists (ACOG) also recommends screening for hepatitis B and HIV.&#x000a0; Patients with chronic medical conditions should have additional testing specific for the evaluation of that condition.&#x000a0; Aneuploidy screening can begin as early as ten weeks gestation with cell-free DNA in women with prior aneuploidy and women =35 years old.&#x000a0; First-trimester aneuploidy screening generally&#x000a0;occurs between weeks 11-13 and includes nuchal translucency measurement on ultrasound and maternal serum-free BhCG and PAPP-A to detect Down's syndrome and Trisomy 18.&#x000a0;</p>
        <p>
<bold>Second Trimester</bold>
</p>
        <p>Laboratory and ultrasound assessments of fetal genetic disorders and structural abnormalities typically take place between 15-20 weeks gestation in the second trimester.&#x000a0; Since 1984, screening for Down's syndrome has been primarily maternal serum alpha protein levels (MSAFP) levels since a report then found that there was lower MSAFP found in women carrying a Down's syndrome affected fetus.&#x000a0; Elevated hCG, elevated inhibin A and lower levels of unconjugated estriol are also linked with an increased risk of a Down's syndrome affected fetus creating the quad screen.&#x000a0; Elevated MSAFP is associated with fetuses affected by open spina bifida.&#x000a0; More recently, screening for genetic disorders trisomies 13, 18 and 21 have been performed using maternal serum cell-free fetal DNA which is considered a non-invasive prenatal test (NIPT).&#x000a0; In 2012, ACOG published guidelines on NIPT use which includes women with prior aneuploidy and women =35 years old.&#x000a0;&#x000a0;</p>
        <p>According the American Institute of Ultrasound in Medicine (AIUM), second trimester ultrasound assessments should include: &#x000a0;(1) fetal cardiac activity, number, presentation; (2) estimate of amniotic fluid volume; (3) placental location, appearance, and relationship to the internal cervical os; (4) imaging of the umbilical cord, and the number of vessels in the cord; (5) gestational (menstrual) age (via biparietal diameter, head circumference, femoral diaphysis length, abdominal circumference, or average abdominal diameter); (6) fetal weight estimation; (7) maternal anatomy (uterus, adnexal structures, cervix); (8) and fetal anatomic survey.&#x000a0; The fetal anatomic survey includes assessment of: head, face, neck, chest (including a four-chamber view of the fetal heart), abdomen, stomach, kidneys, bladder, abdominal cord insertion site, spine, extremities, and sex. &#x000a0;&#x000a0;</p>
        <p>In the late second trimester (26-28 weeks gestation), most institutions will perform and oral glucose tolerance test (OGTT) to screen for gestational diabetes.&#x000a0; The testing can be done with either a 1 hour 50-gram glucose load or a diagnostic 2 hour 75-gram glucose load.&#x000a0;</p>
        <p>
<bold>Third Trimester&#x000a0;</bold>
</p>
        <p>Third-trimester prenatal testing generally&#x000a0;focuses on maternal wellbeing and reducing fetal morbidity/mortality.&#x000a0; Streptococcus agalactiae (group B streptococci beta-hemolytic, GBS) is a major cause of neonatal morbidity and mortality.&#x000a0; Vaginal screening for GBS typically takes place in the late third trimester (34-37 weeks gestation) so that mothers positive for the bacterium can receive treatment during labor before delivery.&#x000a0; Many institutions also require repeat evaluations of hemoglobin/hematocrit, syphilis serology, and HIV screening.&#x000a0;<xref ref-type="bibr" rid="article-27669.r4">[4]</xref><xref ref-type="bibr" rid="article-27669.r5">[5]</xref><xref ref-type="bibr" rid="article-27669.r6">[6]</xref></p>
      </sec>
      <sec id="article-27669.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>First Trimester</bold>
</p>
        <p>Patients with a higher risk of genetic disorders based on ethnicity&#x000a0;also&#x000a0;should be screened in the first trimester. Cystic fibrosis (CF) is one of the most common genetic diseases in Caucasians and&#x000a0;relatively common in Ashkenazi Jews and Hispanics. The National Institutes of Health (NIH) issued a consensus statement in 1997 indicating that CF testing should be offered to adults with a&#x000a0;family history of CF, to partners of people with CF, to all couples planning a pregnancy, and to couples seeking prenatal testing. Patients of Ashkenazi Jew descent are predisposed to&#x000a0;several genetic disorders.&#x000a0; Both the American College of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics and Genomics (ACMG)&#x000a0;recommend carrier testing for three carrier tests:&#x000a0; Tay-Sachs disease, Canavan disease, and familial dysautonomia along with CF testing in this population. The ACMG also recommends screening for Fanconi anemia group C, Niemann-Pick type A, Bloom syndrome, mucolipidosis type IV, and Gaucher disease to all Ashkenazi Jewish couples. Screening for sickle cell disease should be offered to individuals of African, African-American, Mediterranean basin,&#x000a0;Middle Eastern, and Indian descent.&#x000a0;</p>
        <p>
<bold>Third Trimester</bold>
</p>
        <p>Before delivery, an assessment of fetal position and estimated fetal weight should be documented.&#x000a0;<xref ref-type="bibr" rid="article-27669.r7">[7]</xref><xref ref-type="bibr" rid="article-27669.r8">[8]</xref><xref ref-type="bibr" rid="article-27669.r9">[9]</xref></p>
      </sec>
      <sec id="article-27669.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>At every prenatal visit in the first trimester, maternal vital signs, maternal weight, and urinalysis for glucose, protein, and leukocytes should be evaluated.&#x000a0;</p>
        <p>At every prenatal visit in the second trimester, maternal vital signs, maternal weight, fetal heart rate, uterine fundal height and urinalysis for glucose, protein, and leukocytes should be evaluated.&#x000a0;</p>
        <p>At every prenatal visit in the third trimester, maternal vital signs, maternal weight, fetal heart rate, uterine fundal height and urinalysis for glucose, protein, and leukocytes should be evaluated.&#x000a0;</p>
      </sec>
      <sec id="article-27669.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The key to prenatal screening is patient education provided by an interprofessional team. Besides the general healthcare provider, the obstetrician, dietitian and prenatal nurse should educate the patient on the benefits of prenatal screening. In order for patients to make informed decisions about the wide number of test, they need to understand the limitations and benefits of the testing. The patient should also be informed about the risk of some prenatal tests like amniocentesis&#x000a0;or chorionic villus sampling. It is also important to educate the patient on the possibility of false positives and false negative results especially when testing for genetic or chromosomal disorders. Finally, genetic counselors should always be available when a diagnosis of a chromosomal disorder is diagnosed prenatally. The decision to continue with the pregnancy, adopt or choosing to end the pregnancy is not always easy and is best done with the help of genetic and mental health counselors. <xref ref-type="bibr" rid="article-27669.r10">[10]</xref><xref ref-type="bibr" rid="article-27669.r11">[11]</xref>(Level V)</p>
      </sec>
      <sec id="article-27669.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27669&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27669">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27669/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27669">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27669.s7">
        <title>References</title>
        <ref id="article-27669.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hendrix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arits</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bannink</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Montfoort</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Willekes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>den Hartog</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Al-Nasiry</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The choice for invasive prenatal tests after subfertility.</article-title>
            <source>Hum Fertil (Camb)</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-141</page-range>
            <pub-id pub-id-type="pmid">30264592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chimbari</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Opportunities and obstacles to screening for perinatal depression among women in Zimbabwe: A narrative review of literature.</article-title>
            <source>S Afr J Psychiatr</source>
            <year>2018</year>
            <volume>24</volume>
            <fpage>1127</fpage>
            <pub-id pub-id-type="pmid">30263213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berglas</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>SCM</given-names>
              </name>
            </person-group>
            <article-title>Should prenatal care providers offer pregnancy options counseling?</article-title>
            <source>BMC Pregnancy Childbirth</source>
            <year>2018</year>
            <month>Sep</month>
            <day>27</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>384</fpage>
            <pub-id pub-id-type="pmid">30261849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambert-Messerlian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palomaki</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Fewer women aged 35 and older choose serum screening for Down's syndrome: Impact and implications.</article-title>
            <source>J Med Screen</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>59</fpage>
            <page-range>59-66</page-range>
            <pub-id pub-id-type="pmid">30253677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregg</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Prenatal genetic carrier screening in the genomic age.</article-title>
            <source>Semin Perinatol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-306</page-range>
            <pub-id pub-id-type="pmid">30241949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mastantuoni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saccone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Al-Kouatly</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Paternoster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Alessandro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arduino</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carbone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raffone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Vivo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maruotti</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Berghella</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zullo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Expanded carrier screening: A current perspective.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>230</volume>
            <fpage>41</fpage>
            <page-range>41-54</page-range>
            <pub-id pub-id-type="pmid">30240948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parfieniuk</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zbucka-Kretowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ciborowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kretowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barbas</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Untargeted metabolomics: an overview of its usefulness and future potential in prenatal diagnosis.</article-title>
            <source>Expert Rev Proteomics</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>809</fpage>
            <page-range>809-816</page-range>
            <pub-id pub-id-type="pmid">30239246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stoll</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Optimizing use of existing prenatal genetic tests: Screening and diagnostic testing for aneuploidy.</article-title>
            <source>Semin Perinatol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>296</fpage>
            <page-range>296-302</page-range>
            <pub-id pub-id-type="pmid">30209012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Wapner</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Laboratory considerations for prenatal genetic testing.</article-title>
            <source>Semin Perinatol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>307</fpage>
            <page-range>307-313</page-range>
            <pub-id pub-id-type="pmid">30206017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savarirayan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rossiter</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hoover-Fong</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Irving</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bompadre</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bober</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Kamps</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Mackenzie</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Raggio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>KK</given-names>
              </name>
              <collab>Skeletal Dysplasia Management Consortium</collab>
            </person-group>
            <article-title>Best practice guidelines regarding prenatal evaluation and delivery of patients with skeletal dysplasia.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>219</volume>
            <issue>6</issue>
            <fpage>545</fpage>
            <page-range>545-562</page-range>
            <pub-id pub-id-type="pmid">30048634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27669.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milko</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Rini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Butterfield</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Paquin</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Roche</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Souris</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Evaluating parents' decisions about next-generation sequencing for their child in the NC NEXUS (North Carolina Newborn Exome Sequencing for Universal Screening) study: a randomized controlled trial protocol.</article-title>
            <source>Trials</source>
            <year>2018</year>
            <month>Jun</month>
            <day>28</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>344</fpage>
            <pub-id pub-id-type="pmid">29950170</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
